Versameb AG

Swiss Biotech Association

Member

Versameb is developing a new technology platform for local protein delivery through mRNA induction in multiple disease areas, focusing first on regenerative medicine.

Products, services, technology

VERSAMEB's platform has produced candidates that are at an advanced preclinical stage.

Cooperation possibilities

Versameb is willing to exploit the potential of its proprietary platform with renowned pharmaceutical and biotech companies.

http://versameb.com
info@versameb.com
Prof. Friedrich Metzger

Location

Hochbergerstrasse 60C, 4057 Basel, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2017
Number of employees in Switzerland

1-9

Key business

Core competencies

You may also be interested in

SIX

The Swiss Stock Exchange, representing more than a third of the European life sciences market capitalization and accounting for around 35% of the total market capitalization (as of 7 April 2021), the exchange is one of Europe’s leading listing venues for biotech companies.
Zürich

Not a member

Laevoroc Oncology AG

Founded in 2019, Laevoroc is a privately-owned, Swiss oncology group of companies that leverages word-class technologies, our oncology expertise and extensive R&D and commercial experience to approach innovation in cancer therapeutics in a way that combines the pragmatic with the visionary.
Hünenberg

Member

Rowestil Consulting GmbH

Expertise in exploratory clinical drug/diagnostic development is available across a number of disease areas. Timing of input into the developmental strategy from regulatory and commercial perspectives is important in moving development programs towards success.
6318 Walchwil

Member